Diaclone
Diaclone provided raw material monoclonal and polyclonal antibodies and ELISA/ELISpot/Fluorospot immunoassay kits for inflammation, oncology, and immunology applications, serving Life Science, IVD, Pharma, and Veterinary companies. Since July 2021 it has operated as an integrated brand within Medix Biochemica.
- Company typePrivate
- Founded1986
- HeadquartersBesançon, France
- Headcount11–50
- GTM typeB2B
- OfferingHardware or Manufacturing
What Diaclone does
Diaclone is a provider of raw material monoclonal and polyclonal antibodies, antigens, and ELISA/ELISpot/Fluorospot immunoassay kits used in inflammation, oncology, and immunology research and diagnostic applications. Its technology stack centers on hybridoma-derived antibodies and immunoassay formats — ELISA for sensitive quantification of native and recombinant proteins, and ELISpot/Fluorospot for single-cell-level cytokine secretion analysis — supported by contract manufacturing, contract development, and contract analytical services for IVD raw materials. The company served four primary B2B verticals — Life Science, IVD, Pharma, and Veterinary companies — through a sales-led motion via online ordering and distribution partnerships.
In July 2021, Diaclone was acquired by Medix Biochemica, a Finnish in vitro diagnostics raw material supplier with global operations. As a result, Diaclone no longer operates as an independent entity; its products and scientific capabilities have been integrated into Medix Biochemica's broader catalog spanning more than 15 clinical areas (cardiac markers, infectious diseases, tumor markers, neurology, and others), and are distributed through Medix Biochemica's global e-commerce storefront and international distributor network, including dedicated regional operations such as cnmedixbiochemica.com in China. The acquisition was framed by Medix Biochemica as a means of expanding its monoclonal antibody portfolio and strengthening its Western Europe presence. No independent operating financials, founding date, or headcount were disclosed in the available source material.
Diaclone firmographics
Firmographics- Name
- Diaclone
- Legal name
- Diaclone
- Website
- https://diaclone.com
- Company type
- Private
- Founded year
- 1986
- Operating status
- Acquired
- Headcount range
- 11–50 employees
- Short description
- Diaclone provided raw material monoclonal and polyclonal antibodies and ELISA/ELISpot/Fluorospot immunoassay kits for inflammation, oncology, and immunology applications, serving Life Science, IVD, Pharma, and Veterinary companies. Since July 2021 it has operated as an integrated brand within Medix Biochemica.
- Ownership category
- akta.pro rank
Diaclone industry classification
Industry- Product category
- IVD Raw Materials
- NAICS
- In-Vitro Diagnostic Substance Manufacturing (325413)
- SIC
- In Vitro & In Vivo Diagnostic Substances (2835)
- akta.pro primary industry
- IVD Reagents, Assay Kits & Consumables (Non-instrument) (HLAHAAAM)
- akta.pro secondary industry
- Raw Materials & Critical Reagents Supply (Media/Resins/Cytokines) (HLAGAGAI)
Keywords
Where Diaclone is headquartered
LocationHeadquarters
- HQ city
- Besançon
- HQ country
- France
- HQ region
- Europe
Markets served
Diaclone business model
Business model- GTM type
- B2B
- Offering type
- Hardware or Manufacturing
- Cost components
- Supply Chain, Personnel, Technology or R&D, Operations, Marketing or Sales
Revenue model
- Antibody Products: Sale of raw material monoclonal and polyclonal antibodies for immunoassay applications
- Immunoassay Kits: Sale of ELISA, ELISpot and Fluorospot kits for research use
- Custom Services: Contract-based services including contract manufacturing, development and analytical services
Go-to-market motion1 record
Distribution channels2 records
Marketing channels3 records
Diaclone product offering
Product offeringCore offering
Diaclone manufactured and supplied raw material monoclonal and polyclonal antibodies, antigens, and immunoassay kits (ELISA, ELISpot, and Fluorospot) for research use in inflammation, oncology, and immunology. The company also offered contract manufacturing, contract development, and contract analytical services supporting IVD raw material production. Following the July 2021 acquisition by Medix Biochemica, all products are now sold under the Medix Biochemica portfolio.
Product overview
Diaclone offers a portfolio of monoclonal and polyclonal antibodies, antigens, and immunoassay kits (ELISA, ELISpot, and Fluorospot) for research use in immunology, inflammation, oncology, and veterinary applications. Now integrated into Medix Biochemica following the July 2021 acquisition, these products serve Life Science, IVD, Pharma, and Veterinary companies. The company also provides contract-based services including contract manufacturing, development, and analytical services. Diaclone products are now accessible through Medix Biochemica's global distribution network and product catalog.
Differentiator
Problem solved
Functional benefit
Products and services
- Monoclonal and Polyclonal Antibodies
Companies that use Diaclone
Customer profileSegments4 records
Ideal customer profiles4 records
Diaclone technology and API
TechnologyTechnology focussed No
API detail
- Has API
- No
- API docs
- API detail
Core technology
AI maturity
App detail
Feature3 records
Diaclone partnerships and signals
Strategic signalPartnerships
One partnership is on record.
- Medix BiochemicacoreMedix Biochemica acquired Diaclone in July 2021, a well-established provider of raw material monoclonal antibodies and ELISA/ELISpot immunoassays in inflammation, oncology and immunology. This acquisition expanded Medix Biochemica's portfolio with complementary scientific and technological capabilities and strengthened the company's Western Europe presence. All Diaclone products are now integrated into Medix Biochemica's product portfolio.
Scale indicators1 record
Recent moves4 records
Expansion highlights4 records
Diaclone competitors and assessment
Company assessmentMarket position
Competitive moat3 records
Key risks5 records
Key highlights6 records
Customer concentration
Diaclone financial estimates
Financial estimateRevenue estimate
Valuation estimate
Diaclone leadership team
Management profileNumber of profiles
Diaclone funding detail
Funding detailFunding overview
Funding rounds
Investors
Funding detail is available on the Subscription and Enterprise plan.Contact sales →
Diaclone M&A and investment
M&A and investmentM&A
Investments
M&A and investment is available on the Subscription and Enterprise plan.Contact sales →
Frequently asked questions about Diaclone
What does Diaclone do?
Diaclone manufactured and supplied raw material monoclonal and polyclonal antibodies, antigens, and immunoassay kits (ELISA, ELISpot, and Fluorospot) for research use in inflammation, oncology, and immunology. The company also offered contract manufacturing, contract development, and contract analytical services supporting IVD raw material production. Following the July 2021 acquisition by Medix Biochemica, all products are now sold under the Medix Biochemica portfolio.
Is Diaclone a public or private company?
Diaclone is a private company. It is classified as corporate owned and is currently acquired.
When was Diaclone founded?
Diaclone was founded in 1986. It employs 11 to 50 people.
Where is Diaclone based?
Diaclone is headquartered in Besançon, France, in the Europe region.
How does Diaclone make money?
Three revenue lines are on record. Antibody Products are the primary driver. The others are immunoassay Kits and custom Services.
Does Diaclone have an API?
No public API is recorded for Diaclone.
What industry is Diaclone in?
Diaclone's product category is IVD Raw Materials. Its primary akta.pro industry code is HLAHAAAM, IVD Reagents, Assay Kits & Consumables (Non-instrument), with a secondary code of HLAGAGAI, Raw Materials & Critical Reagents Supply (Media/Resins/Cytokines). Its NAICS code is 325413 and its SIC code is 2835.